PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number. the Paperwork Reduction Act of 1995, no persons are required to res

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Dated: November 8, 2005

pond to a collection of information unless it displays a valid OMB control nur					
	Application Number	10/735461-Conf. #3119			
	Filing Date	December 11, 2003			
	First Named Inventor	Michael P. CZECH			
	Art Unit	1635			
	Examiner Name	J.B. Ashen			
	Attorney Docket Number	UMY-055			

(Debra J. Milasincic)

L		
EN	ICLOSURES (Check all that app	oly)
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for Refund	Return Receipt Postcard Copies of Thirty-three (33)
x Information Disclosure Statement	CD, Number of CD(s)	References
Certified Copy of Priority Document(s)	Landscape Table on CD	
Reply to Missing Parts/ Incompl ate Appl ication	Remarks	•
Reply to Missing Parts under 37 CFR 1.52 or 1.53		
	M	
	FRE OF APPLICANT, ATTORNEY, OF	RAGENT
Firm Name LAHIVE & COCKFIE	ŧup, kuk	
Signature		•
Printed name Debra J. Milasincic		
Date November 8, 2005	Reg. No.	46,931
I hereby certify that this correspondence is to an envelope addressed to: MS Amendment	peing deposited with the U.S. Postal pervice	h sufficient postage as First Class Mail, in exandria, VA 22313-1450, on the date



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandra, VA 22313-1450, on the date shown below.

Dated: November 8, 2005 Sign

AParto I Milosipoio

Docket No.: UMY-055

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Michael P. Czech et al.

Application No.: 10/735461

Confirmation No.: 3119

Filed: December 11, 2003

Art Unit: 1635

For:

METHOD OF INTRODUCING siRNA INTO

Examiner: J.B. Ashen

ADIPOCYTES

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/735461 Docket No.: UMY-055

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-055. A

duplicate copy of this paper is enclosed.

Dated: November 8, 2005

DJM/JAM/mch

Debra J. Milasincic

Registration No.: 46,931

LAHIVE & COCKFIELD, LLP

28 State Street

Respectfully s

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



Sheet

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

2

Complete if Known				
Application Number	10/735461-Conf. #3119			
Filing Date	December 11, 2003			
First Named Inventor	Michael P. CZECH			
Art Unit	1635			
Examiner Name	J.B. Ashen			
Attorney Docket Number	UMY-055			

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
						Г		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Alessi, Dario, et al., "3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase," <i>Current Biology, Vol.</i> 7:776-789 (1997)	
	C2	Brazil, Derek P., et al., "Ten years of protein kinase B signalling: a hard Akt to follow," <i>Trends in Biochemical Sciences, Vol.</i> 26(11):657-664 (2001)	
	C3	Brummelkamp, Thijn R., et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," Science, Vol. 296:550-553 (2002)	
	C4	Calegari, Federica, et al., "Tissue-specific RNA interference in postimplantation mouse embryos with endoribonuclease-prepared short interfering RNA," <i>PNAS</i> , Vol. 99(22):14236-14240 (2002)	
	C5	Calera, Monica R., et al., "Insulin Increases the Association of Akt-2 with Glut4-containing Vesicles," <i>The Journal of Biological Chemistry, Vol.</i> 273(13):7201-7204 (1998)	
	C6	Chiu, Ya-Lin, et al., "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA," <i>Molecular Cell, Vol.</i> 10:549-561 (2002)	
	C7	Cho, Han, et al., "Akt1/PKBα Is Required for Normal Growth but dispensable for Maintenance of Glucose Homeostasis in Mice," <i>The Journal of Biological Chemistry</i> , Vol. 276(42):38349-38352 (2001)	
	C8	Cho, Han, et al., "Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)," Science, Vol. 292:1728-1731 (2001)	
	C9	Cohen, Philip, et al., "The renaissance of GSK3," Molecular Cell Biology, Vol. 2:769-776 (2001)	
	C10	Cross, Darren A.E., et al., "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kniase B," <i>Nature, Vol.</i> 378:785-789 (1995)	
	C11	Elbashir, Sayda M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature, Vol.</i> 411:494-498 (2001)	
	C12	Harrison, Scott A., et al., "Insulin Regulation of Hexose Transport in Mouse 3T3-L1 Cells Expressing the Human HepG2 Glucose Transporter," <i>The Journal of Biological Chemistry</i> , Vol. 265(33):20106-20116 (1990)	
	C13	Hill, Michelle M., et al., "A Role for Protein Kinase Bβ/Akt2 in Insulin-Stimulated GLUT4 Translocation in Adipocytes," <i>Molecular and Cellular Biology, Vol.</i> 19(11):7771-7781 (1999)	
	C14	Kohn, Aimee D., et al., "Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation," <i>The Journal of Biological Chemistry, Vol.</i> 271(49):31372-31378 (1996)	

Examiner		Date	
Signature		Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/735461-Conf. #3119	
11	NFORMATION	1 DI:	SCLOSURE	Filing Date	December 11, 2003	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Michael P. CZECH	
				Art Unit	1635	
•	(Use as many she	eets as	necessary)	Examiner Name	J.B. Ashen	
Sheet	2	of	2	Attorney Docket Number	UMY-055	

C15	Kotani, Ko, et al., "Requirement of Atypical Protein Kinase Cλ for Insulin Stimulation of Glucose Uptake but Not for Akt Activation in 3T3-L1 Adipocytes," <i>Molecular and Cellular Biology, Vol.</i> 18(12):6971-6982 (1998)	
C16	Lee, Nan Sook, et al., "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells," nature biotechnology, Vol. 19:500-505 (2002)	
C17	Lewis, David L., "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," nature genetics, Vol. 32:107-108 (2002)	·
C18	McManus, Michael T., "Gene silencing using micro-RNA designed hairpins," RNA, Vol. 8:842-850 (2002)	
C19	Miyagishi, Makoto, et al., "U6 promoter-driven siRNAs wtih four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells," nature biotechnology, Vol. 19:497-500 (2002)	
C20	Okabe, Masataka, et al., "Translational repression determines a neuronal potential in Drosophila asymmetric cell division," <i>Nature, Vol.</i> 411:94-98 (2001)	
C21	Paddison, Patrick J., et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalina cells," Genes & Development, Vol. 16:948-958 (2002)	
C22	Paul, Cynthia P., et al., "Effective expression of small interfering RNA in human cells," nature biotechnology, Vol. 29:505-508 (2002)	
C23	Scherr, Michaela, et al., "Gene Silencing Mediated by Small Interfering RNAs in Mammalian Cells," Current Medicinal Chemistry, Vol. 10:245-256 (2003)	
C24	Sharp, Phillip A., "RNA interference - 2001," Genes & Development, Vol. 15:485-490 (2001)	
C25	Spiller, David G., et al., "Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation," <i>Blood, Vol.</i> 91(12):4738-4746 (1998)	
C26	Sui, Guangchao, et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," PNAS, Vol. 99(8):515-5520 (2002)	
C27	Summers, Scott A., et al., "Differentiation-dependent Suppression of Platelet-derived Growth Factor Signaling in Cultured Adipocytes," <i>The Journal of Biological Chemistry, Vol.</i> 274(34):23858-23867 (1999)	
C28	Tuschl, Thomas, "Expanding small RNA interference," nature biotechnology, Vol. 20:446-448 (2002)	
C29	Ueki, Kohjiro, et al., "Potential Role of Protein Kinase B in Insulin-induced Glucose Transport, Glycogen Synthesis, and Protein Synthesis," <i>The Journal of Biological Chemistry</i> , Vol. 273(9);5315-5322 (1998)	·
C30	Wang, Qinghua, et al., "Protein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts," <i>Molecular and Cellular Biology, Vol.</i> 19(6):4008-4018 (1999)	
C31	Williams, Michayla R., et al., "The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells," <i>Current Biology, Vol.</i> 10:439-448 (2000)	
C32	Yu, Jenn-Yah, et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , <i>Vol.</i> 99(9):6047-6052 (2002)	
C33	Zeng, Yan, et al., "Both natural and Designated Micro RNAs Can Inhibit the Expression of Cognate mRNAs When Expressed in Human Cells," <i>Molecular Cell</i> , Vol. 9:1327-1333 (2002)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.




Application No. (if known): 10/735461

Attorney Docket No.: UMY-055

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:



Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 227-7400

Telephone Number

Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal

Information Disclosure Statement

IDS (Citation) by Applicant (33 References)

Copies of Thirty-three (33) References Return Receipt Postcard